BERGENBIO ANNOUNCES POSTER PRESENTATION AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2021
Bergen, Norway, 01 October 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it will deliver an e-poster presentation at the Society for Immunotherapy of Cancer (SITC) 36[th] Annual Meeting, taking place online from 10-14 November 2021. Abstract titles have been announced online at the SITC website. Details of the presentation are below. Title: AXL targeting with bemcentinb restores PD-1 blockade sensitivity of